Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Clinical Drug Investigation

Volumn 38, Issue 6, 2018, Pages 481-490

  Goldsmith, David ^a   Dellanna, Frank ^b   Schiestl, Martin ^c   Krendyukov, Andriy ^d   Combe, Christian ^e,f  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b MVZ DaVita Rhein Ruhr GmbH   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Sandoz Pharma Ltd   (Switzerland)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; EPO PROTEIN, HUMAN; ERYTHROPOIETIN;

ACUTE HEART INFARCTION; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; CEREBROVASCULAR DISEASE; CONVULSION; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG SAFETY; EUROPE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION ENCEPHALOPATHY; IMMUNOGENICITY; KIDNEY DISEASE; LUNG EMBOLISM; PRIORITY JOURNAL; PURE RED CELL ANEMIA; DRUG SURVEILLANCE PROGRAM;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; ERYTHROPOIETIN; EUROPE; HUMANS; PHARMACOVIGILANCE;

EID: 85045139085     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-018-0637-1     Document Type: Article

References (59)

1. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943.
2. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37:395–402.
3. Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17:97.
4. van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ. 2010;13:241–56.
5. KDIGO. Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl. 2012;2:299–310.
6. Wish JB. The approval process for biosimilar erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2014;9:1645–51.
7. European Medicines Agency. Guideline on similar biological medicinal products. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 25 Jan 2018.
8. European Medicines Agency. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 25 Jan 2018.
9. European Medicines Agency. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf Accessed 25 Jan 2018.
10. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf Accessed 25 Jan 2018.
11. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–17.
12. Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first US biosimilar. Expert Opin Biol Ther. 2016;16:137–42.
13. US Food and Drug Administration. Biosimilarity guidelines. November 2015. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm. Accessed 14 June 2017.
14. Webster CJ, Woollett GR. A ‘global reference’ comparator for biosimilar development. BioDrugs. 2017;31:279–86.
15. Curigliano G, O’Connor DP, Rosenberg JA, Jacobs I. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016;104:131–7.
16. Weise M, Kurki P, Wolff-Holz E, Bielsky M-C, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6.
17. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.
18. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.
19. European Medicines Agency. European public assessment report variation, Aranesp-H-332-X-42. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000332/WC500026148.pdf. Accessed 14 June 2017.
20. ICH. ICH harmonized tripartite guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. 2004. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed 14 June 2017.
21. Halim LA, Brinks V, Jiskoot W, et al. Quality and batch-to-batch consistency of original and biosimilar epoetin products. J Pharm Sci. 2016;105:542–50.
22. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010;28:28–31.
23. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28:386–93.
24. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacother J Hum Pharmacol Drug Ther. 2005;25:954–62.
25. Covic A, Abraham I. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. Int Urol Nephrol. 2015;47:1529–39.
26. Gianoncelli A, Bonini SA, Bertuzzi M, et al. An integrated approach for a structural and functional evaluation of biosimilars: implications for erythropoietin. BioDrugs. 2015;29:285–300.
27. Sorgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.
28. Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D. 2011;11:61–75.
29. European Medicines Agency. Retacrit scientific discussion. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf. Accessed 14 June 2017.
30. European Medicines Agency. Binocrit scientific discussion. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf. Accessed 14 June 2017.
31. Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30:451–60.
32. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77:8–17.
33. Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.
34. Rubic-Schneider T, Kuwana M, Christen B, et al. T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. Blood Adv. 2017;1:367–79.
35. Casadevall N, Dobronravov V, Eckardt KU, et al. Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients. Clin Nephrol. 2017;88:190–7.
36. ® nephrology indication. 2016. https://www.novartis.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar. Accessed 14 June 2017.
37. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88–92.
38. Goldsmith D, Gesualdo L. Biosimilar epoetins in nephrology—where are we now? Eur Nephrol. 2012;6:21–4.
39. Leung LK, Mok K, Liu C, Chan SL. What do oncologists need to know about biosimilar products? Chin J Cancer. 2016;35:91.
40. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473–85.
41. D’Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. BioDrugs. 2016;30:27–32.
42. Minutolo R, Bolasco P, Chiodini P, et al. Effectiveness of switch to erythropoiesis-stimulating agent (ESA) biosimilars versus maintenance of ESA originators in the real-life setting: matched-control study in hemodialysis patients. Clin Drug Investig. 2017;37:965–73.
43. Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. 2013;69:929–36.
44. Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K, Epo-PASS Study Group. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol. 2012;78:24–32.
45. Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–15.
46. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625–37.
47. Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27:105–17.
48. Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72:380–90.
49. London G, Mann J, Goldsmith D, et al. Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. Clin Nephrol. 2018;89:1–9.
50. Dellanna F, Fluck RJ, Lonnemann G, Wild CA, Iwanowitsch A, Meissner R, Audhya P. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: the PASCO I study. Clin Nephrol. 2015;84:280–8.
51. Ingrasciotta Y, Giorgianni F, Marciano I, et al. Comparative effectiveness of biosimilar, reference product and other Erythropoiesis-Stimulating Agents (ESAa) still covered by patent in chronic kidney disease and cancer patients: an italian population-based study. PLoS One. 2016;17(11):5.
52. Trotta F, Belleudi V, Fusco D, et al. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open. 2017;7:e011637.53. GaBI Online. Biosimilars approved in Europe: June 2017 update. 2017. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed 14 June 2017.
53. IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals. 2010.
54. Lemery SJ, Ricci MS, Keegan P, McKee AE, Pazdur R. FDA’s approach to regulating biosimilars. Clin Cancer Res. 2017;23:1882–5.
55. Wish JB, Charytan C, Chertow GM, et al. Introduction of biosimilar therapeutics into nephrology practice in the United States: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2016;68:843–52.
56. US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Guidance for industry: draft guidance. 2017. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 14 June 2017.
57. Kurki P, van Aerets L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31:83–91.
58. US Food and Drug Administration. Filgrastim-sndz. 2015. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436648.htm. Accessed 16 Dec 2016.
59. US Food and Drug Administration. Briefing Document: BLA125545 “Epoetin Hospira”, a proposed biosimilar to Epogen/Procrit (epoetin alfa). 2017. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559967.pdf. Accessed 14 June 2017.